InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By By Modality (RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi), By Phase ((Phase I, Phase II, Phase III, & Phase IV)), By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), Region, Market Outlook And Industry Analysis 2031”


The global RNA Therapy Clinical Trials Market is estimated to reach over USD 3.32 billion by 2031, exhibiting a CAGR of 3.6% during the forecast period. 


Request for Sample Pages:


Synthetic mRNA molecules are supplied to cells to instruct them to create specific proteins in mRNA treatment. This can be utilized to stimulate an immune response against infectious pathogens or generate therapeutic proteins to treat various disorders. The success of mRNA-based COVID-19 vaccines (Pfizer-BioNTech and Moderna vaccines) revealed the power of RNA technology in eliciting an effective immune response. Regulatory bodies, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have expressed a desire to speed up the examination and approval of promising RNA medicines. This assistance sped up the creation of RNA-based medications. On the other hand, the rising use of mRNA in cancer vaccines is likely to drive market expansion throughout the projection period. Numerous clinical trials are presently being done to treat melanoma, colorectal, and pancreatic cancer with an mRNA vaccine.

List of Prominent Players in the RNA Therapy Clinical Trials Market:

  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • PPD Inc.
  • Novotech
  • Veristat, LLC.



Market Dynamics:


Due to mRNA vaccinations’ effectiveness and RNA therapeutics’ possibility, pharmaceutical corporations, venture capitalists, and government agencies have made significant investments. This infusion of cash aided in expanding research and clinical studies in this discipline. Regulatory agencies such as the FDA and EMA saw the potential of RNA treatments and demonstrated a willingness to provide faster review and approval processes. This assistance aided in the development and commercialization of RNA-based medications.



The efficient and targeted transport of RNA molecules to the desired cells or tissues remains a significant challenge. Developing safe and effective delivery technologies that preserve RNA from degradation and assure selective targeting is critical for good RNA therapy outcomes. The creation of RNA therapeutics necessitates extensive research and development efforts. Protecting intellectual property rights can be difficult, primarily when numerous companies and researchers work on comparable technologies.


Regional Trends:

The North American RNA Therapy Clinical Trials Market is expected to witness a significant market share and is projected to rise at a high CAGR shortly. Research activities for RNA-based therapeutics are increasing in North America due to the development of adequate infrastructure for developmental research, the availability of significant research funds, and growing government initiatives towards RNA-based therapeutics, which are expected to drive the RNA-based therapeutics market growth. The Food and Drug Administration (FDA) of the United States has proactively encouraged the development of RNA-based medicines. The FDA has established expedited approval paths for certain RNA treatments, particularly those that address unmet medical needs.


Curious about this latest version of the report? @


Recent Developments:

  • In June 2023, Charles River Laboratories International, Inc. and Curigin have established an alliance to manufacture adenoviral vectors. The gene therapy company will rely on Charles River’s market-leading experience in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical studies. Curigin creates anticancer gene therapy solutions that combine revolutionary genetically engineered viruses and new RNAi technology to block crucial disease-specific genetic signal pathways rapidly and precisely, thereby turning off tumor-causing genes.

Segmentation of RNA Therapy Clinical Trials Market-

By Modality-

  • RNA interference
  • Antisense therapy
  • Messenger RNA
  • Oligonucleotide, non-antisense, non-RNAi)

By Clinical Trials Phase-

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Therapeutic Areas-

  • Rare Diseases
  • Anti-infective
  • Anticancer
  • Neurological
  • Alimentary/Metabolic
  • Musculoskeletal
  • Cardiovascular Respiratory
  • Sensory
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa


For More Customization @


About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: [email protected]
Site Visit:
Follow Us on LinkedIn @
Follow Us On Facebook @

Follow Us @


Subscribe Our Exclusive Newsletters @


See Campaign:

Contact Information:

InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: [email protected] Site Visit: Follow Us on LinkedIn @ Follow Us On Facebook @ Follow Us @ Subscribe Our Exclusive Newsletters @

Extended Distribution, iCN Internal Distribution, Research Newswire, English